SWOG clinical trial number
S9914

Phase II Trial of Paclitaxel, Carboplatin and Topotecan with G-CSF in Untreated Patients with Extensive Small Cell Lung Cancer

Closed
Phase
Accrual
99%
Published
Abbreviated Title
Chemo in Untreated Extensive SCLC
Activated
10/15/1999
Closed
06/15/2001
Participants
NCORP, Members, Medical Oncologists

Research committees

Lung Cancer

Treatment

Paclitaxel Carboplatin Filgrastim Topotecan

Eligibility Criteria Expand/Collapse

Patients must have histologically or cytologically confirmed diagnosis of extensive SCLC; pts. with controlled brain mets (i.e. who are without symptoms or who have had their mets treated with radiation and/or surgery) are eligible; pts. must have measurable or evaluable dz; pts. must have adequate renal, hepatic and hematologic function as outlined in Section 5.0; no prior systemic chemo, biologic or radiation therapy for SCLC; at least two weeks must have elapsed since surgery (thoracic or other major surgeries) with recovery from all toxicities and pts. must have measurable or evaluable dz outside the area of previous surgical resection or a new lesion must be present.

Publication Information Expand/Collapse

2016

Comorbidities and Risk of Chemotherapy-Induced Peripheral Neuropathy Among Participants 65 Years or Older in Southwest Oncology Group Clinical Trials

D Hershman;C Till;J Wright;D Awad;S Ramsey;W Barlow;L Minasian;J Unger Journal of Clinical Oncology Sep 1;34(25):3014-3022; 2016 Jun 20 [Epub ahead of print]

PMid: PMID27325863 | PMC number: PMC5012713

Comorbidities and risk of chemotherapy induced peripheral neuropathy among participants in SWOG clinical trials

DL Hershman;C Till;JD Wright;D Awad;S Ramsey;W Barlow;L Minasian;J Unger Journal of Clinical Oncology 34, 2016 (suppl; abstr 10001); American Society of Clinical Oncology Annual Meeting (June 3-7, 2016, Chicago, IL), oral presentation

2006

Phase II trial of paclitaxel, carboplatin and topotecan with G-CSF support in previously untreated patients with extensive stage small cell lung cancer: Southwest Oncology Group 9914

PJ Hesketh;J McCoy;FR DunphyII;JD Bearden III;GR Weiss;JK Giguere;JN Atkins;SR Dakhil;K Kelly;JJ Crowley;DR Gandara Journal of Thoracic Oncology 1(9):991-995

2002

Southwest Oncology Group Trial (SWOG) 9914: phase II trial of paclitaxel, carboplatin and topotecan (PCT) in untreated patients (pts) with extensive small cell lung cancer (SCLC).

F Dunphy;P Hesketh;K Chansky;DR Gandara Proc of the American Society of Clinical Oncology 21:297a(#1184)

Other Clinical Trials

SWOG Clinical Trial Number
S2302

PRAGMATICA - LUNG: A PROSPECTIVE RANDOMIZED STUDY OF RAMUCIRUMAB (LY3009806; NSC 749128) PLUS PEMBROLIZUMAB (MK-3475; NSC 776864) VERSUS STANDARD OF CARE FOR PARTICIPANTS PREVIOUSLY TREATED WITH IMMUNOTHERAPY FOR STAGE IV OR RECURRENT NON-SMALL CELL LUNG CANCER
Research Committee(s)
Lung Cancer
Activated
03/06/2023
Accrual
65%
Open
Phase
SWOG Clinical Trial Number
A082002

A Randomized Phase II/III Trial of Modern Immunotherapy Based Systemic Therapy with or Without SBRT for PD-L1-Negative, Advanced Non-Small Cell Lung Cancer
Research Committee(s)
Lung Cancer
Activated
12/21/2021
Open
Phase
SWOG Clinical Trial Number
CTSU/NRG-LU007

RAndomized Phase II/III Trial Of Consolidation Radiation + Immunotherapy for ES-SCLC: RAPTOR Trial
Research Committee(s)
Lung Cancer
Activated
08/17/2020
Open